Ovarian cancer-associated antigen (OCAA)

Ovarian cancer antigens represent a broad class of tumor-associated antigens (TAAs) that are abnormally expressed or overexpressed in ovarian malignancies compared to normal ovarian tissue. This category includes well-characterized proteins such as Mucin 16 (CA-125), Folate Receptor Alpha (FRα), Mesothelin, and Human Epididymis Protein 4 (HE4). Biologically, these molecules often contribute to the aggressive phenotype of ovarian cancer by promoting cell-cell adhesion, peritoneal seeding, and escaping immune detection (Source: NIH, PubMed). From a therapeutic perspective, these antigens serve as docking sites for targeted therapies; for example, Mirvetuximab soravtansine targets FRα to deliver a cytotoxic payload, significantly improving outcomes in platinum-resistant cases (Source: FDA, Journal of Clinical Oncology). While highly useful for diagnostics and treatment, the heterogeneity of antigen expression across different histological subtypes remains a significant challenge for universal targeting.

Other names

Ovarian tumor-associated antigensOvarian cancer markersTumor-specific antigens of the ovaryTAAs

Targeting strategies include monoclonal antibodies that induce antibody-dependent cellular cytotoxicity (ADCC), antibody-drug conjugates (ADCs) that deliver antimitotic agents (e.g., DM4) directly to cells expressing the antigen, and radioimmunotherapy. Some agents act as vaccines to stimulate a host immune response against cells displaying these antigens.